Funding for this research was provided by:
Fujian Provincial Health & Family Planning Commission (2016-ZQN-32)
Fujian Provincial Department of Science and Technology (2018J01306, 2018Y2003, 2017Y9079)
Fujian Provincial Platform for Medical Laboratory Research&Key Laboratory for Tumor Individualized Active Immunity (FYKFKT- 2017015)
Received: 30 December 2018
Accepted: 20 March 2019
First Online: 28 March 2019
Ethics approval and consent to participate
: This retrospective study was approved by Fujian Province Cancer Hospital (No. K201427) Institutional Review Board. All patients provided written informed consent prior to treatment, and all information was anonymized prior to analysis.
: Not applicable.
: The authors declare the submitted work was not carried out in the presence of any personal, professional or financial relationships that could potentially be construed as a conflict of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.